• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Entrada Therapeutics Inc.

    5/14/25 12:28:53 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ENTRADA THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    29384C108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29384C108


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,121,654.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,121,654.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,121,654.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    29384C108


    1Names of Reporting Persons

    Janus Henderson Biotech Innovation Master Fund Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,884,826.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,884,826.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,884,826.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IV


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENTRADA THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    ONE DESIGN CENTER PLACE, SUITE 17-500 BOSTON, MA 02210
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    29384C108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 2,119,017 shares
    (b)Percent of class:

    5.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2119017

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2119017

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
     
    Janus Henderson Biotech Innovation Master Fund Ltd
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $TRDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entrada Therapeutics Inc.

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      11/14/24 1:22:40 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Entrada Therapeutics Inc.

      SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      6/26/24 4:54:17 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      2/14/24 4:26:22 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quart

      6/2/25 4:30:00 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

      – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. "ELEVATE-45-201 is the most advanced clinical

      5/28/25 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Entrada Therapeutics Inc.

      DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

      6/3/25 7:45:52 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

      6/3/25 7:05:10 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Entrada Therapeutics Inc.

      SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      5/14/25 12:28:53 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Radhakrishnan Maha

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/3/25 8:13:04 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Radhakrishnan Maha

      3 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/3/25 8:11:16 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Wentworth Kory James exercised 11,134 shares at a strike of $2.10, increasing direct ownership by 10% to 120,670 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      4/4/25 4:34:29 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Entrada Therapeutics with a new price target

      ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

      12/6/24 8:19:11 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

      Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

      1/5/24 8:45:46 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Entrada Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00

      4/3/23 7:39:53 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

      āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

      9/17/24 8:30:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

      BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

      8/10/23 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kim Peter S bought $364,672 worth of shares (25,000 units at $14.59), increasing direct ownership by 37% to 92,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/16/24 4:33:48 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $63,306 worth of shares (4,476 units at $14.14), increasing direct ownership by 7% to 67,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/10/24 4:35:37 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $35,290 worth of shares (2,600 units at $13.57), increasing direct ownership by 4% to 62,936 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      4/10/24 4:35:18 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care